Abstract
ABSTRACTIntroduction: Most new antineoplastic agents (NAAs) must undergo a complex and subject-to-uncertainty selection process before they are included in Hospital Formularies. The aim of this study is to quantify the temporal differences for NAA inclusion across Spanish hospitals and to identify the potential predictive factors for actual access times.Methods: A panel of NAAs approved by the Spanish Drug and Sanitary Products Agency from 2000 to 2010 was studied. A Cox regression model was performed in order to detect the potential predictors of time to NAA inclusion across hospitals.Results: Disparities in time to NAA access were identified. Several factors were found to be associated with faster access, the most important hospital participation in clinical trials. Orphan product designation, among others, was related to delayed access.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
